Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The Potential Effects of the Ketogenic Diet in the Prevention and Co-Treatment of Stress, Anxiety, Depression, Schizophrenia, and Bipolar Disorder: From the Basic Research to the Clinical Practice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI Publishing
    • الموضوع:
    • نبذة مختصرة :
      Background: The ketogenic diet (KD) has been highly developed in the past for the treatment of epileptic pathological states in children and adults. Recently, the current re-emergence in its popularity mainly focuses on the therapy of cardiometabolic diseases. The KD can also have anti-inflammatory and neuroprotective activities which may be applied to the prevention and/or co-treatment of a diverse range of psychiatric disorders.
      Purpose: This is a comprehensive literature review that intends to critically collect and scrutinize the pre-existing research basis and clinical data of the potential advantageous impacts of a KD on stress, anxiety, depression, schizophrenia and bipolar disorder.
      Methods: This literature review was performed to thoroughly represent the existing research in this topic, as well as to find gaps in the international scientific community. In this aspect, we carefully investigated the ultimate scientific web databases, e.g., PubMed, Scopus, and Web of Science, to derive the currently available animal and clinical human surveys by using efficient and representative keywords.
      Results: Just in recent years, an increasing amount of animal and clinical human surveys have focused on investigating the possible impacts of the KD in the prevention and co-treatment of depression, anxiety, stress, schizophrenia, and bipolar disorder. Pre-existing basic research with animal studies has consistently demonstrated promising results of the KD, showing a propensity to ameliorate symptoms of depression, anxiety, stress, schizophrenia, and bipolar disorder. However, the translation of these findings to clinical settings presents a more complex issue. The majority of the currently available clinical surveys seem to be moderate, usually not controlled, and have mainly assessed the short-term effects of a KD. In addition, some clinical surveys appear to be characterized by enormous dropout rates and significant absence of compliance measurement, as well as an elevated amount of heterogeneity in their methodological design.
      Conclusions: Although the currently available evidence seems promising, it is highly recommended to accomplish larger, long-term, randomized, double-blind, controlled clinical trials with a prospective design, in order to derive conclusive results as to whether KD could act as a potential preventative factor or even a co-treatment agent against stress, anxiety, depression, schizophrenia, and bipolar disorder. Basic research with animal studies is also recommended to examine the molecular mechanisms of KD against the above psychiatric diseases.
    • References:
      Aging Dis. 2022 Jul 11;13(4):1146-1165. (PMID: 35855338)
      Front Nutr. 2024 Feb 08;11:1322509. (PMID: 38389795)
      Epilepsia. 2007 Jan;48(1):59-65. (PMID: 17241208)
      Am J Psychiatry. 1965 May;121:1110-1. (PMID: 14283310)
      Psychosomatics. 2006 Mar-Apr;47(2):178-9. (PMID: 16508034)
      Neurodegener Dis Manag. 2022 Apr;12(2):57-66. (PMID: 35179078)
      Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1475-1479. (PMID: 31336509)
      Schizophr Res. 2017 Nov;189:208-209. (PMID: 28162810)
      Front Neurosci. 2022 Jul 22;16:909762. (PMID: 35937892)
      Bipolar Disord. 2015 Jun;17(4):450-7. (PMID: 25495884)
      Epilepsia. 2008 Nov;49 Suppl 8:3-5. (PMID: 19049574)
      Front Mol Neurosci. 2017 May 15;10:129. (PMID: 28555095)
      Nutrients. 2023 Sep 27;15(19):. (PMID: 37836444)
      Brain Behav. 2015 Feb;5(2):e00300. (PMID: 25642385)
      Psychiatr Pol. 2022 Dec 31;56(6):1345-1363. (PMID: 37098202)
      JAMA Psychiatry. 2021 Mar 1;78(3):261-269. (PMID: 33237285)
      Eur J Clin Nutr. 2013 Aug;67(8):789-96. (PMID: 23801097)
      Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90. (PMID: 11256685)
      Front Neurol. 2019 Aug 13;10:849. (PMID: 31456736)
      Nutrients. 2024 Apr 19;16(8):. (PMID: 38674903)
      Epilepsy Behav. 2021 Nov;124:108327. (PMID: 34627070)
      Prog Cardiovasc Dis. 2023 Mar-Apr;77:78-85. (PMID: 36871888)
      Science. 2013 Jan 11;339(6116):211-4. (PMID: 23223453)
      Sci Rep. 2017 Aug 9;7(1):7677. (PMID: 28794421)
      Cureus. 2022 Mar 31;14(3):e23684. (PMID: 35505754)
      Schizophr Bull Open. 2021 Jan 30;2(1):sgaa073. (PMID: 33554120)
      Front Psychiatry. 2021 May 25;12:636174. (PMID: 34113269)
      Nutr Metab (Lond). 2009 Feb 26;6:10. (PMID: 19245705)
      Curr Opin Clin Nutr Metab Care. 2023 Jul 1;26(4):369-376. (PMID: 37265176)
      Curr Probl Cardiol. 2024 Mar;49(3):102402. (PMID: 38232923)
      Front Psychiatry. 2019 May 23;10:363. (PMID: 31178772)
      Bipolar Disord. 2002 Feb;4(1):75. (PMID: 12047499)
      Front Psychiatry. 2024 Feb 14;15:1358578. (PMID: 38419903)
      Nat Med. 2015 Mar;21(3):263-9. (PMID: 25686106)
      Neurosci Lett. 2022 Jan 23;770:136443. (PMID: 34990761)
      Br J Psychiatry. 2017 May;210(5):333-341. (PMID: 28209591)
      Schizophr Res. 2019 Apr;206:244-250. (PMID: 30466960)
      Nutrients. 2021 Apr 15;13(4):. (PMID: 33920973)
      Nutrition. 2024 Aug;124:112420. (PMID: 38669832)
      Schizophr Res. 2015 Dec;169(1-3):491-493. (PMID: 26547882)
      Cold Spring Harb Perspect Biol. 2015 Apr 01;7(4):. (PMID: 25833846)
      Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109913. (PMID: 32151695)
      Neurosci Lett. 2017 Mar 6;642:158-162. (PMID: 28189745)
      Front Cell Neurosci. 2017 Feb 14;11:30. (PMID: 28261061)
      Endocrinology. 2018 Jan 1;159(1):400-413. (PMID: 29077838)
      Ann Neurol. 2006 Aug;60(2):223-35. (PMID: 16807920)
      Mol Psychiatry. 2016 Nov;21(11):1504-1510. (PMID: 26782057)
      Epilepsy Res. 2020 Nov;167:106454. (PMID: 32987244)
      J Behav Med. 2022 Jun;45(3):416-427. (PMID: 35084637)
      Nutrients. 2023 Aug 22;15(17):. (PMID: 37686712)
      Physiol Behav. 2019 Dec 1;212:112654. (PMID: 31430441)
      Med Hypotheses. 2020 Dec;145:110299. (PMID: 33091780)
      Med Hypotheses. 2018 Sep;118:74-77. (PMID: 30037619)
      Biol Psychiatry. 2018 May 1;83(9):739-750. (PMID: 29217297)
      Curr Opin Psychiatry. 2019 Sep;32(5):394-401. (PMID: 31192814)
      BJPsych Open. 2019 Jul 04;5(4):e58. (PMID: 31530294)
      Adv Exp Med Biol. 2023;1411:537-554. (PMID: 36949325)
      Front Nutr. 2021 Nov 23;8:782657. (PMID: 34888340)
      J Neural Transm (Vienna). 2023 Sep;130(9):1195-1205. (PMID: 36943505)
      Neurosci Lett. 2008 Mar 21;434(1):66-70. (PMID: 18281154)
      Psychiatry Res. 2024 May;335:115866. (PMID: 38547601)
      Neurochem Res. 2019 Jan;44(1):22-37. (PMID: 30027365)
      Front Nutr. 2023 Jul 27;10:1191903. (PMID: 37575322)
      Am J Clin Nutr. 2007 Sep;86(3):580-7. (PMID: 17823420)
      Front Psychiatry. 2022 Jul 06;13:951376. (PMID: 35873236)
      J Psychiatr Res. 2024 Jun;174:230-236. (PMID: 38653031)
      BJPsych Open. 2023 Oct 10;9(6):e176. (PMID: 37814952)
      Epilepsy Res. 2012 Jul;100(3):278-85. (PMID: 22771252)
      Front Mol Neurosci. 2016 Dec 06;9:137. (PMID: 27999529)
      Front Nutr. 2022 Jul 05;9:960922. (PMID: 35866077)
      Brain Behav Immun. 2020 Aug;88:748-762. (PMID: 32413556)
      Arch Intern Med. 2009 Nov 9;169(20):1873-80. (PMID: 19901139)
      Neurocase. 2013;19(5):423-6. (PMID: 23030231)
      Circ Res. 2008 Feb 29;102(4):401-14. (PMID: 18309108)
    • Contributed Indexing:
      Keywords: animal studies; anxiety; bipolar disorder; carbohydrates restriction; clinical human studies; depression; ketogenic diet; psychiatric disorders; schizophrenia; stress
    • الموضوع:
      Date Created: 20240619 Date Completed: 20240619 Latest Revision: 20240625
    • الموضوع:
      20240625
    • الرقم المعرف:
      PMC11174630
    • الرقم المعرف:
      10.3390/nu16111546
    • الرقم المعرف:
      38892480